Q32 Bio Inc. - Common Stock QTTB 深 滬
已收盤 07-18 16:00:00 美东时间
2.195
-0.125
-5.39%
華盛通- 最 高2.4168
- 今 開2.32
- 成交量 60.97万股
- 最 低 2.1501
- 昨 收 2.32
- 總市值 2677.37万
- 52周最高 53.79
- 市盈率 靜 --
- 換手率 5.00%
- 52周最低 1.345
- 委 比 0.00%
- 總股本 1219.76万
- 歷史最高 572.40
- 量 比 0.24
- 振 幅 11.50%
- 歷史最低 1.345
- 每 手 1
- 風險率 19.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.
07-11 19:37
Q32 Bio names interim chief medical officer
Clinical-stage biotechnology company Q32 Bio (NASDAQ:QTTB) appointed Adrien Sipos, M.D., Ph.D., as interim chief medical officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departin...
06-25 19:52
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM...
06-25 18:59
Q32 Bio Board Member Mark Iwicki Resigns
The latest announcement is out from Q32 Bio ( ($QTTB) ). On April 25, 2025, Mar...
04-26 04:35
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
美股大行评级 | 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106863358302064640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元</p> <p>• HC Wainwright & Co.：维持LifeMD(LFMD)"买入"评级，目
03-13 09:38
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a ...
03-11 18:59
美股大行评级 | 潜在涨幅119%！Compass医疗获杰富瑞升目标价至8美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1096354625327304705.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Jones Trading：上调In8bio(INAB)评级至"买入"，目标价1.2美元</p> <p>• 丰业银行：维持INmune Bio(INMB)"跑赢大市"评级，目标价从22美元升至23美元</p> <p>•
02-12 09:54
Q32 cut to neutral by Piper on ADX-097 discontinuation
Piper Sandler has downgraded Q32 (NASDAQ:QTTB) to neutral from overweight, citing the company's decision to discontinue its drug ADX-097 before presenting data from a renal basket study. The investmen...
02-12 00:51
Q32 Bio Restructures to Focus on Bempikibart Development
Q32 Bio ( ($QTTB) ) has shared an announcement. On February 10, 2025, Q32 Bio a...
02-11 05:29
